Andrew S. Epstein - Concepedia

Author

Andrew S. Epstein

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

A Epstein, A. Epstein, A. S. Epstein, A.S. Epstein, Andre S Epstein, Andrew Epstein, Andrew S Epstein, Andrew S. Epstein

188

Publications

5.5K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Weill Cornell Medicine Massachusetts General Hospital Dana-Farber Cancer Institute

About

Andrew S. Epstein is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	15	1.2K
2	Nursing	5	5	224
3	Arts	3	3	78
4	Health Sciences	2	2	147
5	Public Health	1	1	14

Andrew S. Epstein

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer Luis A. Rojas, Zachary Sethna, Kevin C. Soares, Nature	2023	1.1K
Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology Harold J. Burstein, Lada Krilov, Jeanny B. Aragon‐Ching, Journal of Clinical Oncology Cancer ManagementImmunologyPathologyAmerican SocietyAnnual Report	2017	599
Discussions of Life Expectancy and Changes in Illness Understanding in Patients With Advanced Cancer Andrew S. Epstein, Holly G. Prigerson, Eileen M. O’Reilly, Journal of Clinical Oncology	2016	225
Palliative Care for Patients With Cancer: ASCO Guideline Update Justin J. Sanders, Sarah Temin, Arunangshu Ghoshal, Journal of Clinical Oncology	2024	209
Identification of germline genetic mutations in patients with pancreatic cancer Erin Salo‐Mullen, Eileen M. O’Reilly, David P. Kelsen, Cancer	2015	200
Randomized Controlled Trial of a Video Decision Support Tool for Cardiopulmonary Resuscitation Decision Making in Advanced Cancer Angelo E. Volandes, Michael K. Paasche‐Orlow, Susan L. Mitchell, Journal of Clinical Oncology	2012	169
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer Zachary Sethna, Pablo Guasp, Charlotte Reiche, Nature Cancer ImmunosurveillancePancreatic CancerImmunologyPathologyImmunotherapy	2025	165
Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology John V. Heymach, Lada Krilov, Anthony J. Alberg, Journal of Clinical Oncology Cell TherapyCancer ManagementImmunologyImmunoeditingPathology	2018	137
NCCN Guidelines® Insights: Palliative Care, Version 2.2021 Maria Dans, Jean S. Kutner, Rajiv Agarwal, Journal of the National Comprehensive Cancer Network Palliative CareNursingPrimary CarePatient SupportEnd-of-life Care	2021	113
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline <i>BRCA</i> mutation carriers and wild‐type <i>BRCA</i> pancreatic ductal adenocarcinoma Eileen M. O’Reilly, Jonathan W. Lee, Maeve A. Lowery, Cancer	2018	103

Page 1